WALTHAM, Mass.--(BUSINESS WIRE)--
ImmunoGen, Inc. (IMGN), a biotechnology company that develops targeted anticancer therapeutics, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 26, 2013, to discuss ImmunoGen's financial results for the three-month period ended March 31, 2013 – the third quarter of the Company’s 2013 fiscal year.
To access the live call by phone, dial 913-312-0843. Passcode: 4566767. The call also may be accessed through the Investor Information section of the Company's website, www.immunogen.com. Following the live webcast, a replay of the call will be available at the same location through May 10, 2013.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's Targeted Antibody Payload (TAP) technology uses a tumor-targeting monoclonal antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. Ten TAP compounds are now in the clinic, of which three are wholly owned by the Company. The most advanced compound using ImmunoGen's TAP technology, KADCYLA (formerly T-DM1), has been approved for marketing in the US and is undergoing regulatory review in Europe and Japan; it is being commercialized in the US by Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.
- Health Care Industry
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153